← Back to Search

Other

CSJ117 for Chronic Obstructive Pulmonary Disease

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2, 6 and 12 weeks
Awards & highlights

Study Summary

This trial is testing a new COPD medication to see if it's effective, how it works in the body, and if it's safe.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2, 6 and 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2, 6 and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in E-RS score
Secondary outcome measures
Accumulation ratio (Racc) of CSJ117
Change from baseline in CAT score
Change from baseline in SGRQ-C score
+11 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: CSJ117 8mgExperimental Treatment1 Intervention
Intervention: Drug: CSJ117
Group II: CSJ117 4mgExperimental Treatment1 Intervention
Intervention: Drug: CSJ117
Group III: CSJ117 PlaceboPlacebo Group1 Intervention
Intervention: Drug: Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CSJ117
2021
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,856 Previous Clinical Trials
4,197,667 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Missouri
Iowa
How old are they?
65+
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
2021. "Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04882124.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top